ESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today reports that revenue during the first half of 2015 is in line with its plans at $28 million. As a result, the Company affirms its previously reported full year 2015 revenue guidance in the range of $70 million to $73 million.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
